Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
WO2021020550A1
Guide rna for targeted-editing with functional base sequence added thereto
WO2021020535A1
Pharmaceutical composition for otic administration
WO2020241903A1
Method for treating muscular dystrophy by targeting dmpk gene
WO2020204142A1
Medicinal composition
WO2020189755A1
Thrombin-loaded hemostatic sheet
WO2020166679A1
Pharmaceutical composition for lowering intraocular pressure
WO2020162422A1
Treatment of retinal degenerative disease by introduction of cx3cl1 gene using adeno-associated virus
WO2020145228A1
Complex comprising ligand and ceacam5 antibody fab fragment
WO2020138404A1
Method for producing nanoparticles including metal particles containing iron oxide having at least one hydrophilic ligand coordinated thereto
WO2020138389A1
Nanoparticle, contrast agent for magnetic resonance imaging comprising same and zwitterionic ligand compound
WO2020101042A1
Method for treating muscular dystrophy by targeting utrophin gene
TW202035459A
Anti-human fn14 antibody
WO2020075746A1
Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
TW202027769A
Cancer therapy where oncolytic vaccinia virus and immune checkpoint inhibitor are used in combination, and pharmaceutical composition and combination drug used therein
CA3108993A1
Pharmaceutical composition for oral administration
WO2021024020A1
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2020027083A1
Pharmaceutical composition comprising quinazoline compound as active ingredient
WO2020027084A1
Pharmaceutical composition comprising quinazoline compound as active ingredient
AU2019304781A1
Fatty acid derivative labeled with positron-emitting radionuclide
